ERBB2 and gastric cancer: This study confirmed the positive results of the main clinical trial—a study of Herceptin (trastuzumab) in combination with chemotherapy compared with chemotherapy alone in patients with HER2-positive advanced gastric cancer (ToGA study) in Germany [54].